KRAS-Variant HNSCC Outcomes May Improve With Cetuximab
Patients with head and neck cancer whose disease is associated with KRAS variant had significantly better progression-free survival and overall survival when treated with the monoclonal antibody cetuximab, according to findings of a retrospective analysis of a randomized trial.
Fewer GI, GU Toxicities With Postoperative Pelvic IMRT in Gynecologic Malignancies
Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.
Dr. Marshall on ASCENDE-RT Trial for Prostate Cancer
January 13th 2016David T. Marshall, MD, MS, professor, director, Medical Residency Program, Department of Radiation Oncology, Medical University of South Carolina, discusses the ASCENDE-RT trial, which compared dose-escalated external beam radiation therapy versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer.
Dr. Kuske on APBI Via Multicatheter Interstitial Brachytherapy
November 26th 2015Robert R. Kuske, MD, radiation oncologist, Arizona Breast Cancer Specialists, discusses the analysis of the Pooled Registry of Multicatheter Interstitial Sites Experience, which examined the safety of accelerated partial breast irradiation via multicatheter interstitial brachytherapy.
Dr. Vicini on Accelerated Partial Breast Irradiation in Low-Risk Breast Cancer
October 29th 2015Frank A. Vicini, MD, radiation oncologist, 21st Century Oncology of Michigan, discusses a European study that examined the efficacy of accelerated partial breast irradiation versus conventional whole breast irradiation in patients with low-risk breast cancer.
Accelerated Partial Breast Irradiation Demonstrates Efficacy in Low-Risk Breast Cancer
October 25th 2015Rates of overall survival, disease-free survival, and local control were found to be comparable in select patients with early-stage breast cancer who underwent accelerated partial breast irradiation using multicatheter brachytherapy versus conventional whole breast irradiation.
Combining Radiotherapy With Anti-Androgen Improves Prostate Cancer Survival
The additon of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial.
Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases
October 23rd 2015Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer and brain metastases.
Dr. Fernandez Discusses Immunotherapy Plus Radiation Therapy for Prostate Cancer
October 6th 2014Eduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.
Blood-Based Biomarkers Predict Outcomes Following Neoadjuvant Treatment in Esophageal Cancer
High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Potentially Curative Surgery Achievable With Chemo/SABR Combination for Advanced Pancreatic Cancer
September 16th 2014The combination of chemotherapy and stereotactic ablative radiotherapy (SABR) may allow patients with locally advanced pancreatic cancer to undergo surgery, a procedure that might not have otherwise been an option
Vessel-Sparing Radiation Preserves Sexual Function in Men With Prostate Cancer
September 16th 2014With the use of MRI imaging to restrict doses to erectile tissues, nearly half of men treated with external beam radiation therapy (EBRT) for prostate cancer were able to be sexually active without aids or medications 5 years later, and nearly 80% could be sexually active if such support was an option
Abbreviated Course of ADT + Radiation Improves QoL in High-Risk Prostate Cancer
September 16th 2014When given along with radiation therapy to men with high-risk prostate cancer, 18 months of androgen-deprivation therapy (ADT)-as opposed to a 36-month course-not only generates similar long-term outcomes, but results in a better quality of life